An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
1 Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK.
2 Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK. simon.travis@ndm.ox.ac.uk.
3 Translational Gastroenterology Unit, Experimental Medicine Division, Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK. simon.travis@ndm.ox.ac.uk.
1 Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK.
2 Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK. simon.travis@ndm.ox.ac.uk.
3 Translational Gastroenterology Unit, Experimental Medicine Division, Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK. simon.travis@ndm.ox.ac.uk.
Endoscopic scoring systems in Crohn's disease and ulcerative colitis aim to translate the assessment of mucosal disease activity into a quantified value. This value seeks to provide a clear, objective record of the endoscopic mucosal severity, which can then be used to guide medical management decisions. The primary driver of all endoscopic indices, however, is to define a scale of responsiveness for therapeutic endpoints in clinical trials. Mucosal healing now has widespread acceptance as a therapeutic and clinical endpoint, but despite the development of multiple endoscopic scoring systems, the endoscopic definition has yet to be resolved. This review describes recent advances in endoscopic scoring systems for ulcerative colitis (Mayo Clinic endoscopy subscore, UCEIS, and UCCIS among others) and for Crohn's disease.
Keywords:
Crohn’s disease; Endoscopy; Mayo score; UCEIS; Ulcerative colitis.
Falvey JD, Hoskin T, Meijer B, Ashcroft A, Walmsley R, Day AS, et al. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission. Inflamm Bowel Dis. 2015;21(4):824–31. doi: 10.1097/MIB.0000000000000341.
-
DOI
-
PubMed
Walsh A, Palmer R, Travis S. Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity. Gastrointest Endosc Clin N Am. 2014;24(3):367–78. doi: 10.1016/j.giec.2014.03.005.
-
DOI
-
PubMed
Sakuraba A, Annunziata ML, Cohen RD, Hanauer SB, Rubin DT. Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn’s disease. Inflamm Bowel Dis. 2013;19(12):2577–83. doi: 10.1097/MIB.0b013e3182a8df32.
-
DOI
-
PubMed
Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology. 2012;142(5):1102–11 e2. doi: 10.1053/j.gastro.2012.01.035.
-
DOI
-
PubMed
Ferrante M, Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, et al. Validation of endoscopic activity scores in patients with Crohn’s disease based on a post hoc analysis of data from SONIC. Gastroenterology. 2013;145(5):978–86.e5. doi: 10.1053/j.gastro.2013.08.010.
-
DOI
-
PubMed
